The GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function

Abstract Aims/hypothesis The glucagon-like peptide-1 receptor (GLP1R) is a key regulator of glucose homeostasis and body weight, and a major therapeutic target for type 2 diabetes and obesity. Individual disease risk and response to treatments may vary widely depending on the presence of missense variants (MVs) in the GLP1R gene, but accurate prediction of the impact of MVs in the G protein-coupled receptor (GPCR) remains challenging. Here we aimed to generate a reliable and GPCR-tailored predictor of the impact of MVs that is applicable for precision medicine. Methods We developed a GPCR variant impact predictor (GPCR VP score) by combining molecular dynamics (MD) simulations with available machine-learning/AI-based models (AlphaMissense and REVEL) to substantially improve the predictive performance of existing models. MD simulations of wild-type and mutant GLP1R complexes were used to extract GPCR-specific structural and dynamic features that capture membrane context, allosteric communication, and mutation-induced contact rearrangements. These descriptors were integrated with existing variant-effect predictors (AlphaMissense and REVEL) and trained on 58 experimentally characterised GLP1R variants to develop GPCR VP , a GPCR-specific variant predictor. Results The GPCR VP predictor showed strong agreement with experimental data and robust performance on independent validation datasets. Notably, it demonstrated a substantial reduction in false-positive predictions (approximately 78%) in the validation sets compared with AlphaMissense, indicating improved specificity and reliability. Generation of structural models for all known human GLP1R MVs (174 outside the training and validation sets) produced a comprehensive resource showing the predictive impact of all GLP1R MVs. Conclusions/interpretation These findings establish the GPCR VP score as a GPCR-specific and reliable predictor for GLP1R MVs that is likely to be of great relevance for clinical decision-making without the time- and cost-consuming generation of experimental data.

Authors

Institutions

Publication Details

Journal
Diabetologia
Published
2026-09-17
DOI
https://doi.org/10.1007/s00125-026-06859-3
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

The GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function

Marta Lopez‐Balastegui, Florence Gbahou, Julie Dam, Tomasz Maciej Stępniewski et al.
Diabetologia
Genomics and Rare Diseases
article

The GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function

Marta Lopez‐Balastegui, Florence Gbahou, Julie Dam, Tomasz Maciej Stępniewski, Ralf Jockers, Jana Selent, Wenwen Gao, Shuangyu Lian
article en

Abstract

Abstract Aims/hypothesis The glucagon-like peptide-1 receptor (GLP1R) is a key regulator of glucose homeostasis and body weight, and a major therapeutic target for type 2 diabetes and obesity. Individual disease risk and response to treatments may vary widely depending on the presence of missense variants (MVs) in the GLP1R gene, but accurate prediction of the impact of MVs in the G protein-coupled receptor (GPCR) remains challenging. Here we aimed to generate a reliable and GPCR-tailored predictor of the impact of MVs that is applicable for precision medicine. Methods We developed a GPCR variant impact predictor (GPCR VP score) by combining molecular dynamics (MD) simulations with available machine-learning/AI-based models (AlphaMissense and REVEL) to substantially improve the predictive performance of existing models. MD simulations of wild-type and mutant GLP1R complexes were used to extract GPCR-specific structural and dynamic features that capture membrane context, allosteric communication, and mutation-induced contact rearrangements. These descriptors were integrated with existing variant-effect predictors (AlphaMissense and REVEL) and trained on 58 experimentally characterised GLP1R variants to develop GPCR VP , a GPCR-specific variant predictor. Results The GPCR VP predictor showed strong agreement with experimental data and robust performance on independent validation datasets. Notably, it demonstrated a substantial reduction in false-positive predictions (approximately 78%) in the validation sets compared with AlphaMissense, indicating improved specificity and reliability. Generation of structural models for all known human GLP1R MVs (174 outside the training and validation sets) produced a comprehensive resource showing the predictive impact of all GLP1R MVs. Conclusions/interpretation These findings establish the GPCR VP score as a GPCR-specific and reliable predictor for GLP1R MVs that is likely to be of great relevance for clinical decision-making without the time- and cost-consuming generation of experimental data.

Diabetologia
Centre National de la Recherche Scientifique (FR), Inserm (FR), Universitat Pompeu Fabra (ES), Jilin University (CN), Université Paris Cité (FR), Barcelona Biomedical Research Park (ES), Biotech Park (IN), Institut Cochin (FR)
Universitat Pompeu Fabra, European Commission, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Centre National de la Recherche Scientifique, HORIZON EUROPE Framework Programme, European Regional Development Fund, Agencia Estatal de Investigación
Openalex Percentile: Top 12%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.